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a b s t r a c t
Neuronal nitric oxide synthase (nNOS) is involved in the regulation of diverse intracellular messenger
systems in the brain. Nitric Oxide (NO) contributes to inducing signaling cascades that involve a complex
pattern of phosphorylation of DARPP-32 (in Thr-34), which controls the phosphoproteins involved in
neuronal activation. However, the role of NO in the pathophysiology of Parkinson’s disease (PD) and its
effect in striatal neurons have been scarcely explored. In the present work, we investigate the effects of
a nitric oxide synthase (NOS) inhibitor, 7-nitroindazole (7-NI) in the nigrostriatal pathway of striatal 6-
hydroxydopamine (6-OHDA) lesioned rats. Our quantitative histological ﬁndings show that treatment
with 7-NI signiﬁcantly reduced 6-OHDA-induced dopaminergic damage in the dorsolateral striatum and
Substantia Nigra pars compacta (SNpc). Moreover, 6-OHDA lesioned rats show a signiﬁcant increase of
nNOSþ and Phospho-Thr34-DARPP-32þ cells, accompanied by a consequent decrease of total DARPP-32þ
cells, which suggests an imbalance of NO activity in the DA-depleted striatum, which is also reﬂected in
behavioral studies. Importantly, these effects are reverted in the group treated with 7-NI. These results
show a clear link between the state of phosphorylation of DARPP-32 and parkinsonism, which is regu-
lated by nNOS. This new evidence suggests a prominent role for nitric oxide in the neurotransmitter
balance within the basal ganglia in the pathophysiology of experimental parkinsonism.
! 2012 Published by Elsevier Ltd.
1. Introduction
Idiopathic Parkinson’s disease (PD) is a common age-related
movement disorder characterized by bradykinesia, rigidity,
resting tremor and postural instability. The neuropathological
hallmarks of PD are the progressive loss of dopaminergic neurons
in the Substantia Nigra pars compacta (SNpc) and the presence of
intraneuronal cytoplasmic inclusions (Lewy bodies) in some
surviving nigral dopaminergic (DA) neurons. The clinical manifes-
tation of PD occurs when about 50% of nigral dopaminergic neurons
and about 70% of striatal dopamine ﬁbres are lost (Hornykiewicz
and Kish, 1987; Von Bohlen Und Halbach, 2004). This loss of DA
ﬁbers in the striatum causes disorganization of the activity of the
striatal neurons, accompanied by a subsequent alteration of the
basal ganglia circuitry with detrimental effects for the patients
concerned.
Q2Nitric oxide (NO) has emerged as a key endogenousmodulator of
the neuronal function, but its role in the regulation of the activity of
striatal neurons and its implication for PD are still unclear. NO is an
intracellular and short-lasting molecule that is synthesized from L-
arginine in several brain regions by a reaction catalyzed by NO
synthase (NOS) (Ignarro,1990;Dawsonet al.,1991). NOS is located in
neurons, perivascular nerves, glial cells and the endothelium (Bredt
and Snyder, 1990; Murphy et al., 1993). The family of NOS, the
enzymes that induce NO, consists of two different classes: the
inducible and constitutive forms (Dawson and Snyder, 1994;
Marletta, 1994). Additionally, among the constitutive forms, there
are two calcium-dependentNOS (cNOS) isoforms: theneuronalNOS
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(nNOS) present in neurons, and the endothelial NOS (eNOS) present
in both pyramidal cells and endothelial cells (Moncada et al., 1991).
Even if both NOS positive cell type have been found in basal
ganglia (Vincent and Kimura, 1992), the function of nNOS in basal
ganglia circuitry remains scarcely explored. In ex vivo striatal slices,
it has been demonstrated that postsynaptic effects of DA are
conferred to a 32 kDa dopamine- and cyclic AMP-regulated phos-
phoprotein (DARPP-32) (Nishi et al., 2005) in striatal projection
neurons, which receive the bulk of DA innervation within the basal
ganglia. Through interactions with multiple kinases and phospha-
tases, DARPP-32 regulates the phosphorylation levels, and thereby
the activity of a broad range of target proteins (Greengard et al.,
1999). In addition to DA, numerous neurotransmitters, peptides
and neuromodulators have been shown to provide input to DARPP-
32-associated signal transduction cascades (Greengard et al., 1999).
This evidence highlights the importance of DARPP-32 as a critical
component of signal integration in striatal projection neurons.
Several recent studies have emphasized a crucial role for the
nitrergic system in movement control and the pathophysiology of
the basal ganglia (Pierucci et al., 2011). The NO produced is diffused
into medium spiny neurons of the striatum, resulting in the
formation of cGMP and activation of protein kinase G (PKG), where
the DARPP-32, an excellent substrate for PKG and protein kinase A
(PKA), is phosphorylated (Tsou et al., 1993; Nishi et al., 2005). These
studies also suggest that the effects of nitric oxide on striatal
neurons are partially mediated via cyclic guanosine mono-
phosphate (cGMP) (West and Tseng, 2011).
However, the role of nNOS in the striatum pathway in parkin-
sonism in vivo is unknown and there are few studies concerning the
inﬂuence of nNOS inhibition on the DA loss in vivo (Hantraye et al.,
1996; Ferrante et al., 1999).
In the present work, we used a speciﬁc inhibitor of nNOS, 7-
nitroindazole (7-NI) (Southan and Szabó, 1996), a relatively selec-
tive inhibitor of the neuronal isoform of nitric oxide synthase, in
a model of PD induced by the intrastriatal injection of 6-OHDA (Di
Matteo et al., 2009), observing that inhibition of nNOS has an
important effect on the regulation of DARPP-32 signaling in the
striatum of hemiparkinsonian rats. This suggests a prominent role
for nNOS in the regulation of the activity of striatal neurons in
parkinsonism.
2. Experimental procedures
2.1. Animals
Sixty-four adult male SpragueeDawley rats weighing
250e300 g (purchased from Harlan) were housed in groups of four
animals per cage in a temperature-controlled room (21 " 1 #C),
under a 12-h lightedark cycle, with free access to food and water.
All animals experiments were carried out in accordance with the
U.K. Animals (Scientiﬁc procedures) Act, 1986, and associated
guidelines, and the European Communities Council Directive of 24
November 1986 (86/609/ECC) for the care and use of laboratory
animals. All efforts were made to minimize animal suffering and to
reduce the number of animals used in these experiments.
2.2. Surgical procedures: 6-OHDA microinjections
The rats were anesthetized with a mixture of ketamine/xylazine
(50 mg/kg; 10 mg/kg i.p.) and placed on a stereotaxic frame (Kopf
Texas Instruments). Unilateral striatal lesions were performed by
microinjecting 6-OHDA with 0.02% ascorbic acid (4 mg/ml, RBI-
Sigma) in 0.9% saline into the right striatum (2 microinjections of
2 ml each) with a 10 ml Hamilton syringe, at a rate of 1 ml/min. The
concentration of 6-OHDAwas selected on the basis of its successful
use for inducing lesions restricted to the dorsolateral striatum in
the rat, which rotated, in response to treatment with apomorphine
(Schwarting and Huston, 1996). To prevent noradrenergic (NA)
failure, 10 min before the 6-OHDA injection, the animals were
treated with desmethylimipramine (inhibitor of the high afﬁnity
noradrenaline transport system, 25 mg/kg i.p., Sigma) and pargy-
line (inhibitor of the monoamino-oxidase enzyme, 40 mg/kg i.p.,
Sigma). The stereotaxic coordinates of the two injections, according
to Paxinos & Watson’s rat brain Atlas (1998), locating the tooth bar
at $2.4 mm, were: (First injection) anterior: 1.20 mm; lateral:
2.5 mm; ventral: $4.5 mm; and (second injection) anterior:
0.48 mm; lateral: 3.4 mm; ventral: $5.0 mm from bregma. Sham-
operated control animals (n ¼ 9) were injected with saline
(vehicle) instead of the neurotoxin using the same procedure. After
the injection, the syringe was left in the target for an additional
2 min before removal.
2.3. Pharmacological treatment
The 7-NI (purchased from RBI-Sigma) administrations started
30 min before the stereotaxic surgery. The inhibitor was dissolved
in peanut oil and administered for 5 days (one per day) at a thera-
peutic dose, previously tested in preliminary experiments, thus
preventing cataleptic behavior in the animals (15 mg/kg, i.p., &5)
(Guevara et al., 2002; Padovan-Neto et al., 2009). Every group,
Sham or lesioned, was divided into two subgroups, treated with
vehicle (peanut oil) or treated with 7-NI: i) Sham þ vehicle (n ¼ 9),
ii) Sham þ 7-NI (n ¼ 9), iii) 6-OHDA þ vehicle (n ¼ 11) and iv)
6-OHDA þ 7-NI (n ¼ 11).
The rats were placed in clean cages onwarming pads bedding to
recover from the surgery, after which theywere returned the group
housing (two or three rats per cage).
2.4. Behavioural tests
2.4.1. Evaluation of rotational behavior
To determine the success of unilateral striatal denervation, rats
were injected with apomorphine hydrochloride (0.5 mg/kg s.c.,
RBI-Sigma) 15 days after the 6-OHDA lesions. The total number of
(contralateral) rotations was recorded every 5 min for 45 min
(Padovan-Neto et al., 2009). Turns were counted by a rotometer
(Ungerstedt and Arbuthnott, 1970) [built in the CAID (Centro de
Apoyo a la Investigación y al Desarrollo) of our university]. The
behavioral evaluation was performed blindly by the observers.
Given that after 6-OHDA lesion small depletions of striatal DAwere
associated with a lower intensity of rotations with apomorphine
(Costall et al., 1976), only animals in the 6-OHDA/Veh group, which
exhibited more than 15 total turns contralateral to the side of the 6-
OHDA lesion, in 45 min, were included in this study.
2.4.2. Elevated body swing test (EBST)
An additional evaluation with EBST was made to verify the
partial striatal lesion (Blandini et al., 2007) and to avoid the
behavioral sensitization effects of repeated apomorphine injec-
tions. The EBST was performed to evaluate 6-OHDA-treated
animals 35 days after the lesion as previously described (Borlongan
and Sanberg, 1995). The animals were placed in a Plexiglas box
(40 & 40 & 35.5 cm) for 2 min for habituation. Then, each rat was
held 3 cm from the base of its tail and suspended approximately
3 cm above the table. In this position the animals start swinging to
the right or left side and the events counted. The animal must
return to the outstretched position for the next swing to be coun-
ted. At the beginning, a gentle pinch in the tail may stimulate the
behavior. The number of left-biased (L) swings and right-biased (R)
swings were counted during a period of 1 min. Biased swinging
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behavior was calculated as follows: L (% of total BS for left-biased
swings) and R (% of total BS for right-biased swings), Total
BS¼ Lþ R. All experimental tests were performed at the same time
of day (Fig. 1, panel A.2).
2.4.3. Tissue preparation
To study the histological effects of the lesion, forty days after the
last behavioral screening, 40 animals were deeply anesthetized
with a mixture of ketamine/xylazine (50 mg/kg; 10 mg/kg i.p.) and
transcardially perfused with PBS 0.01 M (300 ml; pH 7.4) followed
by 4% paraformaldehyde in 0.1 M phosphate buffer (250 ml; pH
7.4). The brains were rapidly removed and postﬁxed in the same
ﬁxative solution for 24 h (4 #C) and then cryoprotected in 30%
sucrose/phosphate buffer. Brains were quickly frozen in cold iso-
pentane ($40 #C; Sigma) and stored at $80 #C until the histo-
chemical and immunocytochemical procedures were carried out.
2.4.4. Immunohistochemistry and histochemistry
Thirty mm-thick serial coronal sections were cut in a cryostat
(Leica). After a period of time, adjacent brain sections containing
CaudateePutamen complex (CPu) nucleus or SNpc were immu-
nostained for TH, DARPP-32 and nNOS. TH immunohistochemistry
was performed as previously described (Barcia et al., 2004), and the
same procedure was carried out for nNOS, total DARPP-32 and the
same protein, phosphorylated at Thr-34. Brieﬂy, tissue sections
were washed and then incubated for 18e24 h with the primary
antibody (TH, 1:1000, Calbiochem; NOS1, 1:1000, Santa Cruz; total
DARPP-32 and DARPP-32 phospho T34, 1:400, Abcam ab51139 and
ab51076, respectively). Sections were processed by the avidin-
biotin immunoperoxidase method (Vectastain ABC kit, Vector
Lab) and immunopositive cells were visualized by addition of the
chromogen 3,30-diaminobenzidine (DAB; Sigma, 1 mg/ml) and
hydrogen peroxide (0.2%). For both DARPP-32, 1% Nickel was added
to visualize the cells with greater contrast. Sections were mounted
on gelatin-coated glass slides, dehydrated in ethanol, cleared in
xylene and cover-slipped for microscopic observations. Cyto-
plasmic DARPP-32 positive cells could be visualized as a blue or
dark blue reaction product, respectively, and nNOS and TH as
a brown precipitate. In all experiments, tissues from Sham and all
lesioned groups were always processed in the same assay.
2.4.5. Western blotting analysis
Ten Sham rats groups and fourteen 6-OHDA rats groups were
killed by decapitation 30 min after the last 7-NI injection. The
Fig. 1. Striatal injections of 6-OHDA causes a mild parkinsonism in rats which is reverted by 7-NI treatment. (A.1) The number of apomorphine-induced turns, 15 days after lesion,
were signiﬁcantly lower in the 6-OHDA/7-NI group than in the 6-OHDA/Veh group. (A.2) The left-biased swings measured by EBST 35 days after lesion in the 6-OHDA/Veh group
were increased by 70% compared with Sham animals. *P < 0.05 lesioned animals vs Sham groups (ANOVA followed by the Duncan test). Photomicrographs show the distribution of
THþ ﬁbers in the dorsolateral striatum (B.1) and THþ neurons in the SNpc (C.2) in the different experimental groups, 45 days post-lesion. Schematics illustrations of the analyzed
coronal section are shown on the right. Each bar of the histograms corresponds to mean " SEM. The treatment with 7-NI moderately attenuated the loss of THþ ﬁbers (B.2) and
protected the cells (C.2) in both structures, respectively (striatum and SNpc), in 6-OHDA-lesioned animals. THþ neurons in the ventral mesencephalon in a section containing the
intra-axial portion of the third craneal-nerve. The three different regions, analyzed of the SN are indicated in the scheme on the right to panel (C.2). In panel (C.1) a graph showing
the count of THþ neurons in the 3 areas of the SN (SNpc, SNg and SNlat). The AP localization of the analyzed Substantia Nigra area was AP $5.80 mm from bregma. We found only
a signiﬁcant difference in the SNpc with respect to other areas (ANOVA, F(3,15) ¼ 3.24, post-hoc Newman-Keuls). *P < 0.05, 6-OHDA/Veh vs Sham/Veh and 6-OHDA/7-NI. OD: Optical
Density, ROD units: Relative Optical Density units.
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brains were removed, and the striata dissected out on an ice-cold
surface. The structure was immediately immersed in liquid
nitrogen. Samples were placed in homogenization buffer [phos-
phate buffered saline, 2% sodium dodecylsulfate (SDS) plus
protease inhibitors (Roche, Germany) and phosphatase inhibitors
Cocktail Set (Calbiochem, Germany)] and homogenized for 50 s
prior to centrifugation at 6000 g for 20 min at 4 #C. Total protein
concentrations were determined spectrophotometrically using the
bicinchoninic acid method (Wiechelman et al., 1988). The optimum
amount of protein to be loaded was determined in preliminary
experiments by loading gels with increasing protein contents
(25e100 mg) from samples of each experimental group. Equal
amounts of protein (50 mg/lane) from each sample were loaded
on a 10% SDSepolyacrylamide gel (SDSePAGE), electrophoresed,
and transferred onto a poly vinylidene diﬂuoride (PVDF)membrane
using a Mini Trans-Blot Electrophoresis Transfer Cell (Bio-Rad Lab.,
California, USA). Non-speciﬁc binding of antibodies was mitigated
by incubating membranes with 1% bovine serum albumin (BSA) in
tris buffer saline tween (TBST: 10 mM TriseHCl, pH 7.6, 150 mM
NaCl, and 0.05% Tween 20). Membranes were immunoblotted
overnight using selective antibodies against Phospho-Thr34-
DARPP-32 (1:1000; Cell Signaling Technology) and Total DARPP-
32 (1:1000; Cell Signaling Technology). After extensive washings
with TBST, the membranes were incubated for 1 h, at room
temperature, with peroxidase-labeled secondary antibodies (anti-
rabbit sc-2004 for DARPP-32 phosphorylated at Thr-34 and Total
DARPP-32, at 1:2000 dilutions). After washing, immunoreactivity
was detected with an enhanced chemiluminescent/chemi-
ﬂuorescent western blot detection system (ECL Plus, GE Healthcare,
U.K) and visualized by a Typhoon 9410 variable mode Imager (GE
Healthcare). Antibodies were stripped from the blots by incubation
with stripping buffer (glycine 25mM and SDS 1%, pH¼ 2), for 1 h at
37 #C. Anti b-actin was used as housekeeper (Cell Signaling,
45 kDa). The ratio of total DARPP-32/b-actin, phospho-DARPP-32/b-
actin was plotted and analyzed.
2.5. Quantitative methods
2.5.1. Immunohistochemistry and histochemistry
The whole histological quantiﬁcation was performed blindly.
Neuroanatomical sites (Dorsolateral striatum and SNpc) were
identiﬁed using the Paxinos and Watson (1998) atlas. The antero-
posterior (AP) localization of the analyzed dorsolateral striatum
area was AP 1.20 mm from bregma (Fig. 1, panel B.1). Stained
neurons were counted using a computerized image analysis
system. Images were captured from slices using a computer-
assisted image analysis system (ImageJ 1.43 Analysis software
from directory at rsb.info.nih.gov/ij/ with a Zeiss microscope con-
nected to a digital camera (CoolSnap) through a Zeiss zoom set at
10& and a 0.1& adapter (Barcia et al., 2004)). The loss of dopami-
nergic ﬁbers in the dorsolateral striatum was analyzed by
measuring the optical density of the TH immunoreactivity with
a computer analyzer (ImageJ System).
The optical density of a tissue area devoid of staining (corpus
callosum) was measured, adjusting the light intensity to give
a background density value. The background was subtracted from
all subsequent measurements. A mean value for staining intensity
was calculated and expressed on an arbitrary gray scale (relative
optical density) units (ROD units; Echeverry et al., 2004). The
boundary of SNpc was outlined under magniﬁcation of the 4&
objective. Cells were counted with a 40& oil-immersion objective
using a Nikon 80i microscope. Serial sections through the whole
SNpcwere placed 6 per slide (cut thickness of 30 mm) for systematic
analysis of randomly placed counting frames (size 50 & 50 mm) on
a counting grid (size of 190 & 130 mm) and sampled using an 18 mm
optical dissector with 2 mmupper and lower guard zones. The nNOS
labeled neurons were quantiﬁed in the dorsolateral region of the
striatum (Fig. 2). For quantiﬁcation of labeled neurons and cyto-
plasmic DARPP-32, an average number from a ﬁxed size/area of the
dorsolateral part of caudate nucleus was observed (Figs. 3e4). For
each treatment, three sections from each animal were evaluated. A
mean value for the number of cells in the three regions of the
animal was then calculated.
2.5.2. Western blot analysis
All the quantiﬁcations for the immunoblot analysis corre-
sponding to total DARPP-32 (32 kDa) and DARPP-32 phosphory-
lated at Thr-34 (32 kDa) bands were carried out by densitometry
(AlphaImager, Nucliber, Madrid). We measured the integrated
optical density of bands. The software generates quantitative data
of band intensities. The values are in units of pixel gray levels and
are proportional to the light intensity on that pixel during the
exposure time of the image. The optical density was normalized to
the background values. Relative variations between bands of
experimental samples and control samples were calculated in the
same image.
2.6. Statistical analysis
All values were expressed as mean " S.E.M. Analysis of
variance (ANOVA) for repeated measures was performed, taking
as intrasubject factor the side of the brain, and the treatment as
the factor between groups to analysis interaction between
factors. In case of effect on treatment factor, differences between
groups were analyzed using one-way ANOVA. The Duncan test
was used for multiple comparison procedures. Differences
between means were analyzed using one-way ANOVA. The
Duncan test was used for multiple comparison procedures.
Pearson r correlation was used to assess any correlation between
the densitometry of TH vs rotational behavior, as well as
between phospho-Thr34-DARPP-32 vs nNOS, TH vs nNOS
and total DARPP-32 vs phospho-Thr34-DARPP-32. For Western
blot analysis we used one-way ANOVA followed by the
NewmaneKeuls post-hoc test. A signiﬁcance level of P < 0.05
was considered to be statistically signiﬁcant.
3. Results
In the left side (contralateral to lesion) in dorsolateral striatum
there was not any alteration by the lesion. (see Table 1).
3.1. 7-NI reverts parkinsonian behavior in 6-OHDA-lesioned rats
The treatment with apomorphine induced contralateral rota-
tions in 6-OHDA-lesioned animals but not in control animals.
However, a signiﬁcant decrease in the number of rotationswas seen
in 7-NI compared to vehicle treated rats (control animals did not
show any rotations (Sham/Vehicle, n ¼ 4; Sham/7-NI, n ¼ 5)
(ANOVA, F(3,19) ¼ 20.70, P < 0.001) (Fig. 1, panel A.1)).
Although stereotyped behavior may be observed as a typical
response to the lesion in the striatum of the rat (Iversen and Koob,
1977; Old et al., 1999), in our animals no signiﬁcant differences
were observed between the experimental groups. The percentage
of left-biased swings measured by EBST ﬁve weeks after the
striatal-lesion was signiﬁcantly higher than in Sham rats (Duncan,
P < 0.05). 6-OHDA/Vehicle animals showed more than a 70%
increase in the number of left-biased swings compared with Sham
animals. A decrease not signiﬁcant, was observed in 6-OHDA/7-NI
animals (Duncan, P > 0.05) (Fig. 1, panel A.2).
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3.2. 7-NI protects the nigrostriatal pathway in 6-OHDA-lesioned rats
Histological analyses were carried out in the dorsolateral stria-
tum region of interest, and in the SNpc area (in the ipsilateral side to
the injection). Previously, an analysis of both sides was performed.
In the dorsolateral striatum region, an interaction (ANOVARepeated
Measures, F(3,16) ¼ 3.31, P ¼ 0.047), and effect in treatment factor
was observed (ANOVARepeatedMeasures, F(3,16)¼5.08, P¼ 0.012).
Densitometry analysis revealed a signiﬁcant reduction of THþ ﬁbers
in the lesioned-dorsolateral striatum of 6-OHDA rats. However,
a signiﬁcant effectwas observed in the 6-OHDA/7-NI group (ANOVA,
F(3,19)¼23.42, P<0.001) (Fig.1, panel B.2). For lesion area, the ratio of
the lesioned area (DA terminal loss) was calculatedwith ImageJ. The
data were expressed in percentage of the total dorsolateral area.
Sham/Veh: No lesion: 100%, Sham/7-NI: No lesion: 100%, 6-OHDA/
Veh: No lesion: 15.5%; Lesion: 84.5% and 6-OHDA/7-NI: No lesion:
37.2%; Lesion: 62.8%. Besides, there was a signiﬁcant negative
correlation between the expression of striatal THþ ﬁbers and rota-
tional behavior (r¼$0.869, P< 0.001). In the SNpc region (but not in
SNlat and SNg), a decrease in THþ neurons was seen in 6-OHDA/
Vehicle animals compared with Sham/vehicle and 6-OHDA/7-NI
groups (ANOVA, F(3,15) ¼ 3.24, P < 0.05; Duncan, P < 0.05) (Fig. 1,
panel C.2).Moreover, in the other areas of the SubstantiaNigra (SNlat
and SNg)wedidnotﬁnd signiﬁcant difference inTHþneurons in any
groups (ANOVA, F(3,15) ¼ 3.24, P > 0.05) (Fig. 1, panel C.1). These
changes were observed in the SNpc, which projects toward the
dorsolateral striatum.
3.3. 7-NI reduces nNOS striatal expression in 6-OHDA-lesioned rats
Effect on treatment factor was observed (ANOVA Repeated
Measures, F(3,15) ¼ 3.52, P ¼ 0.041). The density of nNOS-
immunoreactive positive neurons in the 6-OHDA/Vehicle group
increased in the lesioned-dorsolateral striatum compared with
Sham groups but it was partially reverted in 6-OHDA/7-NI group
(ANOVA, F(3,16) ¼ 6.63, P < 0.005) (Fig. 2, panel B). The density of
nNOS cells was negatively correlated with the density of THþ ﬁbers
(Fig. 5, panel A).
3.4. 7-NI reduces DARPP-32 phosphorylation in 6-OHDA-lesioned rats
To accurately determine the increase in DARPP-32þ cell
numbers in pathophysiological stages in postmortem brain, it is
important to establish a positive control for the quantiﬁcation in
a non-involved brain area. In this case, in all the sections we
analyzed the motor cortex, immediately above the striatum
(Figs. 3e4, panel A) (Ouimet et al., 1984, 1998), also stained for
control area for both total DARPP-32 and phosphoThr-34-DARPP-
32. Analysis with pospho-Thr34-DARPP-32 showed an interaction
between both factors (ANOVA Repeated Measures, F(3,16) ¼ 5.15,
P ¼ 0.011). In lesioned-dorsolateral striatum, the number of pos-
pho-Thr34-DARPP-32 cells was increased in the 6-OHDA/Vehicle
group, which was signiﬁcantly diminished in the 6-OHDA lesioned
group treated with the nNOS inhibitor (ANOVA, F(3,16) ¼ 4.62,
P < 0.01) (Fig. 4, panel D). An opposite effect was observed on the
total DARPP-32þ cell number. Previously, an interaction between
both factors was observed (ANOVA Repeated Measures,
F(3,16) ¼ 21.53, P < 0.001), and an effect on the treatment factor
(ANOVA Repeated Measures, F(3,16) ¼ 19.89, P < 0.001). In lesioned-
dorsolateral striatum, DARPP-32þ cells decreased in the 6-OHDA/
Vehicle group, whereas a signiﬁcant increase was also found in the
6-OHDA/7-NI group (ANOVA, F(3,17) ¼ 27.4, P < 0 .001; Duncan,
P< 0.05) (Fig. 3, panel D). Furthermore, a signiﬁcant correlationwas
seen between the levels of phospho-Thr34-DARPP-32 and total
Fig. 2. Increase of striatal nNOS is reverted by 7-NI. (A) Photomicrographs show nNOS labeling in the dorsolateral striatum. An increase of nNOSþ cells was observed in the 6-OHDA/
Veh group with respect to Sham animals (B) and was slightly lower in the 7-NI treatment (6-OHDA/7-NI). *P < 0.05 6-OHDA vs Sham groups, and #P < 0.05 6-OHDA/7-NI vs Sham/
Veh (ANOVA followed by the Duncan test).
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DARPP-32 (Fig. 5 panel B) which suggests consumption of the total
DARPP-32 phosphorylated by NO mediated mechanisms. This
means that PKG (via NO) phosphorylated total DARPP-32 and that
the protein turns into its phosphorylated form (phospho-Thr34-
DARPP-32). In addition, a very signiﬁcant positive correlation
between nNOS labeling and the expression of pospho-Thr34-
DARPP-32 was observed (r ¼ 0.556, P ¼ 0.01) (Fig. 5, panel C).
Thus, these results demonstrate an association between the state of
phosphorylation of DARPP-32 and nNOS cell number in the
lesioned striatum.
3.5. 7-NI reduces values of phospho-DARPP-32 and increases total
DARPP-32 in 6-OHDA-lesioned rats by western blot analysis
Phospho-Thr43-DARPP-32 and total DARPP-32 immunoblots in
the striatum were examined by Western blot analysis in control
treated with 6-OHDA/Vehicle and treated with 6-OHDAþ 7-NI rats.
As regards DARPP-32, total and phospho-DARPP-32was detected in
a band located atw32 kDa (Figs. 3e4, panel C). In rats treated with
6-OHDA/7-NI, the total DARPP-32 protein increased signiﬁcantly
with respect to controls groups (ANOVA, post-hoc NewmaneKeuls,
P < 0.01, Fig. 3, panel C). Similar results were obtained by
immunohistochemistry. The opposite effect was observed in the
phospho-Thr34-DARPP-32, which increased in the 6-OHDA/Vehicle
group with respect to controls animals (One Way ANOVA, post-hoc
NewmaneKeuls, P < 0.01, Fig. 4, panel C). These data are in
agreement with those obtained by immunohistochemistry, giving
more consistency to the results.
4. Discussion
Based on quantitative immunohistochemical and behavioral
analyses, the present study provides in vivo evidence for the
upregulation of DARPP-32-signaling caused by a moderate DA
depletion in the striatum, controlled by nNOS mediated
mechanisms.
Our results show that a unilateral intrastriatal injection of 6-
OHDA in rats induces a slight loss of THþ ﬁbers in the striatum
andTHþ cells in the SNpc, associatedwith a low intensive rotation to
apomorphine administration (Ungerstedt, 1971; Costall and Naylor,
1975; Herrera-Marschitz and Ungerstedt, 1984; Koob et al., 1984).
Although drug-induced rotational behavior is widely used to eval-
uate the level of DA lesion, a more sensitive test (as we use in our
model) should be used due to the sensitization effects of apomor-
phine. In our rats, this small DA depletion was reliably detected by
rotational behavior and by a signiﬁcant contralateral biased-swing
Fig. 3. Total DARPP-32 in the dorsolateral striatum is reduced by intrastriatal 6-OHDA injections and upregulated by 7-NI. (A) Photomicrographs showing cytosolic DARPP-32
labeling in Motor Cortex (arrowheads), and CaudateePutamen. (B) Photomicrographs show an overall expression of total DARPP-32þ cells in 6-OHDA/7-NI group compared
with the other experimental groups. The quantiﬁcation in the dorsolateral striatum showed a decrease in 6-OHDA/Veh and a striking increase in the 6-OHDA/7-NI group (D).
*P < 0.05 with respect to Sham groups (ANOVA followed by the Duncan test). (C) Normalized values with b-actin were compared with those of the Shams or 6OHDA treatment
groups. **P < 0.01, 6OHDA/Veh vs Shams groups (One way ANOVA followed NewmaneKeuls post-hoc test) and ***P < 0.001, 6OHDA/Veh vs 6OHDA/7-NI (One way ANOVA followed
NewmaneKeuls post-hoc test).
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activity. Therefore, the EBST seems to be a good drug-free
measurement for asymmetrical motor behavior (Borlongan and
Sanberg, 1995). These asymmetries were detected in body swing
behavior revealing a small imbalance of DA output that other anal-
yses may not be sensitive enough to detect (Yuan et al., 2005;
Baluchnejadmojarad and Roghani, 2004). Like the injections of 6-
OHDA in the medial forebrain bundle or the SNpc, unilateral intra-
striatal injections of 6-OHDA in rats could also be considered a good
model for describing progressive loss of DA-containing structures in
PD (Przedborski et al.,1995; Kirik et al.,1998; Debeir et al., 2005) and
hence, a model for studying nNOS regulation and its effects on DA
neurodegenerative processes (Gomes et al., 2008).
As regards the increase in nNOS, our results agree with previous
studies showing that a striatal 6-OHDA lesion causes an increase in
nNOS positive cells in the anterior and middle striatum, with
a signiﬁcant decrease of nNOS density in cells in the SNpc, an effect
that is modiﬁed by NOS inhibitors (Gomes et al., 2008). This
increase of nNOS may be responsible for the increase of NO that
contributes to DA neurodegeneration, but also continuing to the
signaling of projecting neurons of the striatum.
As previously reported,we observed that the administration of 7-
NI prevented the loss of THþ ﬁbers in the striatumandneurons of the
SNpc. This could be explained by the fact that DA depletion in the
striatum increased the oxidative stress exerted by peroxynitrite,
which is recognized as an important mediator of neuronal degen-
eration in the DA system (Smith and Cass, 2007). Subsequently, NOS
inhibitors, such as 7-NI, could protect against oxidation/nitration
processes, reducing the levels of peroxynitrite itself (Denicola and
Radi, 2005), and putatively attenuating 6-OHDA toxicity.
Besides inhibiting nNOS, 7-NI is also a good inhibitor of MAO-B,
and indeed Di Monte and coworkers have attributed to this
mechanism the neuroprotective effect of 7-NI against MPTP inmice
(Di Monte et al., 1997). However, the mechanism of action of 6-
OHDA differs from that of MPTP, and so inhibition of MAO-B is
unlikely to affect 6-OHDA toxicity. Nevertheless, when MAO-B
inhibitors are sub-chronically administered neurorestorative and
neuroprotective effects are observed (Blandini et al., 2004; Sagi
et al., 2007).
On the other hand, this protective effect of NOS inhibition could
also be due to the effect of NO on dopamine transporter (DAT) and/
or to its biochemical interactionwith the 6-OHDA. In fact, since DAT
activity is modulated by NO, and 6-OHDA is a substrate for DAT
(Blum et al., 2001), it is reasonable to propose that NOS inhibition
may lead to a reduction of DAT activity and hence prevent the
access of 6-OHDA to DA terminals (Volz and Schenk, 2004). Besides,
in culturedmesencephalic neurons and organotypic culturemodels
(Gomez-Urquijo et al., 1999), it was demonstrated that some
dopaminergic neurons also express nNOS giving further support for
a pre-synaptic interaction between both systems, and suggesting
a possible effect of nitric oxide on DA uptake, previously veriﬁed
through NO donors and an indirect DA agonist, amphetamine
(Salum et al., 2008).
Fig. 4. Intrastriatal 6-OHDA injections increases phospho-Thr34-DARPP-32 in the dorsolateral striatum and is reverted by 7-NI. (A) Photomicrograph showing cytosolic Phospo-
Thr34-DARPP-32 labeling (arrowheads) in Motor Cortex, and CaudateePutamen. (B) Photomicrographs show an increased expression in 6-OHDA/Veh group compared with the
other experimental groups. Quantiﬁcations of the Phospho-Thr34-DARPP-32 revealed a signiﬁcant increase in 6-OHDA/Veh group that is prevented by 7-NI treatment (D). *P < 0.05
6-OHDA vs the other groups (ANOVA followed by the Duncan test). (C) Normalized values with b-actin were compared with those of Sham or 6-OHDA treatment groups. **P < 0.05
6-OHDA/Veh vs Shams groups and 6-OHDA/Veh vs 6-OHDA/7-NI (One way ANOVA followed by the NewmaneKeuls post-hoc test).
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NO has been shown to diffuse into medium spiny neurons and
activate soluble guanylyl cyclases (sGC), resulting in the forma-
tion of transient increases in intracellular cGMP levels that can
affect to medium spiny neuron (MSN) activity via activation of
PKG and downstream targets (e.g., cyclic nucleotide gated
channels) (West and Grace, 2004; West and Tseng, 2011), which
then causes the increased phosphorylation of DARPP-32 in
threonine residue 34 (Thr-34). This is because DARPP-32 at Thr-
34 is an excellent substrate for PKG as well as PKA and therefore
the activated PKG induces the phosphorylation of DARPP-32 at
Thr-34 (Hemmings et al., 1984; Tsou et al., 1993; Greengard et al.,
1999).
Remarkably consistent outcomes have been reported in studies
examining the impact of DA D1 and D2-like receptor agonists/
antagonists on striatal NOS activity and NO production via cGMP
(Di Stefano et al., 2005; Sammut et al., 2006; Siuciak et al., 2006;
Park and West, 2009; Hoque et al., 2010).
Together, these studies conﬁrm that both D1 and D2-like
receptor activation strongly regulates striatal nNOS activity, albeit
in opposing manners (i.e., D1 receptor activation facilitates the
activity, while, D2 receptor activation is inhibitory), and identify
a critical role of nNOSeNO signaling in the generation of striatal
cGMP.
Glutamate, by activating NMDA and AMPA receptors, stimulates
the synthesis of NO in nNOS interneurons in the neostriatum (Tsou
et al., 1993), and the synthesized NO regulates the function of MSNs
(Calabresi et al., 2000). Glutamate also induces a rapid and tran-
sient increase in DARPP-32 Thr-34 phosphorylation. It is abolished
by inhibitors of nNOS (as well 7-NI) and soluble guanylyl cyclase,
indicating that glutamate activates nNOS in GABAergic interneu-
rons, where nNOS is expressed in the neostriatum (Tsou et al.,
1993).
Once phosphorylated, the DARPP-32 at Thr-34 inhibits protein
phosphatase-1 (PP-1) activity (Svenningsson et al., 2004), acting
as a cAMP-dependent kinase inhibitor (Svenningsson et al., 2004;
Nishi et al., 2005). In fact, in the dorsolateral striatum, phos-
phorylation mechanisms play a physiological role in motor
control, and the induction of both long-term depression (LTD) and
long-term potentiation (LTP), two opposing forms of synaptic
plasticity. Both forms of plasticity (LTP/LTD) are also critically
linked to the activation of DA receptors, supporting the idea that
in the striatum, a close interplay among DA receptors, DARPP-32
state phosphorylated/de-phosphorylated, and glutamatergic
transmission might underlie the functional role of this structure in
motor control and cognitive activities. (Calabresi et al., 2000,
2007).
In the context of experimental parkinsonism, our ﬁndings show
that following dorsolateral striatal lesion with 6-OHDA, there is an
increase in nNOS that may induce the phosphorylation of DARPP-
32 in Thr-34, with a concomitant decrease of total DARPP-32,
suggesting that NO mediates a regulatory effect in experimental
parkinsonism (Fig. 6). Importantly, DARPP-32, located in medium-
sized spiny neurons in most cytosolic subcellular compartments
including dendrites, axons and axon terminals, may provide the
anatomical framework for the action of multiple outputs of the
striatum regulated by NO in PD (Lindskog et al., 2002; Nairn et al.,
2004). In this context, the regulation of DARPP-32 via nNOS may
Table 1
Quantiﬁcation analysis in dorsolateral striatum region in the right and left hemisphere.
THa nNOS Total DARPP-32 Thr34DARPP-32
R L R L R L R L
SHAM/Veh 64.2 " 6.9 60.3 " 4.6 24.4 " 1.5 27.5 " 2.2 181.9 " 13.3 192.3 " 13.4 199.2 " 22.7 214.1 " 12.6
SHAM/7NI 61.1 " 7.9 62.1 " 5.3 28.6 " 2.5 28.4 " 2.0 190.9 " 13.1 182.2 " 4.9 231.0 " 10.1 203.0 " 20.5
60HDA/Veh 12.1* " 2.0 60.1 " 5.4 38.4* " 2.8 29.7 " 0.4 105.9* " 11.6 177.4 " 6.0 274.1* " 13.8 200.9 " 30.1
60HDA/7NI 26.8* " 4.8 58.0 " 5.1 32.1# " 1.0 29.6 " 4.5 295.4* " 20.8 188.6 " 2.3 207.1 " 12.6 215.5 " 2.7
Other data are expressed as numbers of labeled cells/0.5 mm2 and represented with mean " S.E.M. Further speciﬁcations as in results. R ¼ right side and L ¼ left side. Q3
a TH was measured by optical density analysis.
Fig. 5. Correlations of the changes in the dorsolateral striatum after 6-OHDA neuro-
degeneration. (A) Negative correlation between nNOS vs TH (r ¼ $0.595, P ¼ 0.0056,
Pearson r correlation). An increased nNOS expression is associated with a decrease in
TH positive neurons. (B) Negative correlation between Total DARPP-32 vs phospho-
Thr34-DARPP-32 (r ¼ $0.4611, P ¼ 0.041, Pearson r correlation). An increase of total
DARPP-32 expression is associated with a decrease in DARPP-32 phosphorylated
positive neurons. (C) Positive correlation between Phospho-Thr34-DARPP-32 vs nNOS
(r ¼ 0.5562, P ¼ 0.011, Pearson r correlation). An increase of phospho-Thr34-DARPP-32
expression is associated with an increase in nNOS positive cells.
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represent a therapeutic target for controlling the disorganized
activity of medium-sized spiny neurons in DA-depleted striatum in
parkinsonism.
5. Conclusions
This study shows that amild dorsolateral striatal 6-OHDA lesion,
which provokes a signiﬁcant increase of nNOS, is correlated with
a positive balance of phospho-Thr34-DARPP-32 expression in the
neostriatum. Importantly, treatment with 7-NI, apart from
providing a neuroprotective effect, restores the striatal levels of
phosphorylation DARPP-32 and increases the level of total DARPP-
32. These results throw light on the role of NO in regulating the
activity of the striatum, suggesting that nNOS inhibitor may have
a beneﬁcial effect in restoring the neurotransmitter imbalance of
the basal ganglia circuitry in parkinsonism.
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32 and a decrease of DARPP-32 phosphorylated. MSN: medium-sized spiny neuron. NMDAR: NMDA receptor.
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